The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vaccines for the 21st Century: A Tool for Decisionmaking
Age Groups
Populations
Incidence Rates (per 100,000)
% Distribution of Cases
Cases
MORTALITY ASSOCIATED WITH HSV CNS INFECTION
<1
3,963,000
0.00
0.0000
1–4
16,219,000
0.00
0.0000
5–14
38,056,000
0.39
0.2222
150
15–24
36,263,000
0.00
0.0000
25–34
41,670,000
0.00
0.0000
35–44
42,149,000
0.00
0.0000
45–54
30,224,000
0.43
0.1944
131
55–64
21,241,000
0.62
0.1944
131
65–74
18,964,000
0.69
0.1944
131
75–84
11,088,000
1.18
0.1944
131
85+
3,598,000
0.00
0.0000
Total
263,435,000
0.26
1.0000
675
INCIDENCE OF GENITAL HSV INFECTION
<1
3,963,000
0.00
0.0000
1–4
16,219,000
0.00
0.0000
5–14
38,056,000
0.00
0.0000
15–24
36,263,000
275.76
0.3333
100,000
25–34
41,670,000
479.96
0.6667
200,000
35–44
42,149,000
0.00
0.0000
45–54
30,224,000
0.00
0.0000
55–64
21,241,000
0.00
0.0000
65–74
18,964,000
0.00
0.0000
75–84
11,088,000
0.00
0.0000
85+
3,598,000
0.00
0.0000
Total
263,435,000
113.88
1.0000
300,000
adults who experience the acute CNS disease. This chronic condition is assumed to be associated with an HUI of .19 for the duration of the person’s life.
Genital Infections
For the purposes of the calculations in this report, it was assumed that 100% of genital HSV infections are associated with a 2-week period at an HUI of .81 (genital lesions, fever, pain). It is assumed that 90% of infections lead to 10 years of minor recurrences; 10% of infections are associated with 5 years of more severe recurrences.
